7 unknown, 4 not yet recruiting, 2 terminated, 1 recruiting. 9 Phase 2, 3 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Unknown 4, Not yet recruiting 2, Terminated 2, Suspended 1 |
| Not applicable | 3 | Unknown 2, Not yet recruiting 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Borderline Resectable Pancreatic Cancer: new trials by email Literature Review of Borderline Resectable Pancreatic Cancer trials Research Report on Borderline Resectable Pancreatic Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) Gemcitabine Delivered by Transarterial Microperfusion - Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | University of Vermont | 10 | 2026-12-01 | 2026-03-17 |
| Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer IMD10, chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin] - Pancreatic Cancer, Borderline Resectable Pancreatic Cancer | Not applicable | Not yet recruiting | IMGT Co., Ltd. | 360 | 2026-09-01 | 2026-07-15 |
| Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC Surufatinib Plus Iparomlimab and Tuvonralimab and AG Chemotherapy, Gemcitabine plus Capecitabine, Modified FOLFIRINOX - Borderline Resectable Pancreatic Cancer, High-Risk Resectable Pancreatic Cancer | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 56 | 2026-09-01 | 2026-09-22 |
| EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases CTC - CTCs, Pancreatic Cancer | Not yet recruiting | Huazhong University of Science and Technology | 20 | 2026-03-01 | 2026-03-04 | |
| A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer Chemotherapy, Radiology, Pancreatectomy - Locally Advanced Pancreatic Cancer, Borderline Resectable Pancreatic Cancer | Recruiting | Oslo University Hospital | 400 | 2024-12-03 | 2025-04-25 | |
| Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer irinotecan liposome II combined with 5-FU/LV and oxaliplatin - Borderline Resectable Pancreatic Cancer | Phase 2 | Unknown | Peking Union Medical College Hospital | 45 | 2024-04-17 | 2024-07-10 |
| NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab, Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate - Borderline Resectable Pancreatic Cancer | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2024-03-10 | 2024-04-03 |
| AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer Nab paclitaxel plus gemcitabine, mFOLFIRINOX - Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma | Phase 3 | Unknown | Fudan University | 300 | 2021-09-01 | 2022-01-28 |
| Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer Drug GC4711, Placebo - SBRT, Borderline Resectable Pancreatic Cancer | Phase 2 | Terminated | Galera Therapeutics, Inc. | 177 | 2021-05-07 | 2024-05-21 |
| Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC Laparoscopic pancreatoduodenectomy, Open pancreatoduodenectomy - Borderline Resectable Pancreatic Cancer | Not applicable | Unknown | Fudan University | 120 | 2021-04-15 | 2023-05-09 |
| IORT on Borderline Resectable Pancreatic Cancer Intraoperative radiotherapy - Borderline Resectable Pancreatic Cancer | Phase 2 | Suspended | Universita di Verona | 100 | 2019-10-01 | 2024-05-07 |
| Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer nab-paclitaxel and S-1 - Borderline Resectable Pancreatic Cancer | Phase 2 | Unknown | Peking Union Medical College Hospital | 60 | 2019-05-01 | 2020-03-10 |
| Divestment for Artery-involved Pancreatic Cancer Artery Divestment Technique, Nab-paclitaxel - Pancreatic Cancer, Locally Advanced Pancreatic Cancer | Not applicable | Unknown | The First Affiliated Hospital with Nanjing Medical University | 122 | 2018-03-01 | 2018-02-23 |
| Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer FOLFIRINOX, gemcitabine + nab-paclitaxel - Borderline Resectable Pancreatic Cancer | Phase 2 | Unknown | Nagoya University | 50 | 2015-07-01 | 2020-09-10 |
| Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer gemcitabine/nab-paclitaxel, mFOLFIRINOX - Borderline Resectable Pancreatic Cancer | Phase 2 | Terminated | Nathan Bahary, MD | 2 | 2014-12-01 | 2018-07-26 |
Pancreatic Neoplasms (6) · Neoplasm Metastasis (1) · Neoplasms (1) · Recurrence (1)
Digestive System Diseases (6) · Digestive System Neoplasms (6) · Endocrine Gland Neoplasms (6) · Endocrine System Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Pancreatic Diseases (6) · Disease Attributes (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Gemcitabine (4) · Oxaliplatin (4) · 130-nm albumin-bound paclitaxel (3) · Fluorouracil (3) · Drug Therapy (2) · Irinotecan (2) · Leucovorin (2) · Albumin-Bound Paclitaxel (1) · Capecitabine (1) · Diagnostic Imaging (1) · Endoscopy (1) · Pancreatectomy (1) · S 1 (combination) (1) · Surgical Procedures, Operative (1) · Taxes (1)
Fudan University (2) · Peking Union Medical College Hospital (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Galera Therapeutics, Inc. (1) · Huazhong University of Science and Technology (1) · IMGT Co., Ltd. (1) · Nagoya University (1) · Nathan Bahary, MD (1) · Oslo University Hospital (1) · Shanghai Zhongshan Hospital (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Universita di Verona (1) · University of Vermont (1)
China (8) · United States (4) · Canada (1) · France (1) · Italy (1) · Norway (1) · South Korea (1) · United Kingdom (1)
Bin Cheng (1) · Wenming Wu, doctor (1) · Xian-Jun Yu, MD, PhD (1) · Xianjun Yu, MD, PhD (1) · Xiaowu Xu, MD (1)
PMID 24006012, PMID 24635869, PMID 26341722, PMID 28069018, PMID 28338171, PMID 29113659, PMID 29800971, PMID 31892339, PMID 33593311, PMID 33934960, PMID 34145168, PMID 34256456, PMID 34547082, PMID 38039992, PMID 38264869, PMID 38628105, PMID 38781696